CXCR4 and neoplasm: Plerixafor, a competitive CXCR4 inhibitor and a stem cell mobilizer, is effective in inhibiting initial establishment of tumor cells into the bone microenvironment, whereas the same drug is ineffective in containing the expansion of pre-existing bone metastasis.